Researchers sought to determine whether CAR-T therapy could improve HR-QoL scores for patients with relapsed or refractory multiple myeloma.

DataM Intelligence | competitive Intelligence Explore the evolving Multiple Myeloma market: drug innovations, emerging therapies, and key p ...

Early intervention in high-risk smoldering myeloma with lenalidomide delays progression by up to 7 years and achieves ...

The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...

Lynozyfic’s global sales are projected to reach $707 million by 2031.

A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; Carvykti) improved long-term survival among patients with heavily pretreated ...

REGN and partner Sanofi SNY announced mixed results from two late-stage studies, AERIFY-1 and AERIFY-2, on itepekimab for the treatment of chronic obstructive pulmonary disease (COPD).The candidate is ...

Regeneron Pharmaceuticals ... with other cancer treatments in patients with relapsed/refractory (R/R) multiple myeloma (MM). Results presented that linvoseltamab in combination with carfilzomib ...

Regeneron Pharmaceuticals ... study on oncology drug linvoseltamab. LINKER-MM2 is a phase Ib, open-label clinical trial evaluating linvoseltamab in combination with other cancer treatments in patients ...

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary ... or bortezomib in patients with relapsed/refractory (“R/R”) multiple myeloma (“MM”); ...